Kenvue (NYSE:KVUE) Upgraded at Barclays

Barclays upgraded shares of Kenvue (NYSE:KVUE) to a hold rating in a research note issued to investors on Thursday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group started coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Performance

NYSE KVUE opened at $22.21 on Thursday. The company has a 50-day simple moving average of $22.95 and a two-hundred day simple moving average of $21.20. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market cap of $42.58 billion, a price-to-earnings ratio of 40.38, a PEG ratio of 2.02 and a beta of 1.36. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.31 EPS. On average, equities analysts forecast that Kenvue will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.69%. Kenvue’s payout ratio is currently 149.09%.

Institutional Investors Weigh In On Kenvue

A number of institutional investors have recently modified their holdings of the stock. Huntington National Bank grew its holdings in shares of Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after buying an additional 871 shares during the last quarter. ING Groep NV boosted its stake in Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after purchasing an additional 681,954 shares during the last quarter. Kennon Green & Company LLC increased its holdings in shares of Kenvue by 140.7% in the 2nd quarter. Kennon Green & Company LLC now owns 159,106 shares of the company’s stock worth $2,893,000 after purchasing an additional 93,008 shares in the last quarter. Crestwood Advisors Group LLC raised its stake in shares of Kenvue by 14.8% in the second quarter. Crestwood Advisors Group LLC now owns 1,537,348 shares of the company’s stock worth $27,950,000 after purchasing an additional 198,607 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Kenvue by 34.9% during the second quarter. Assenagon Asset Management S.A. now owns 347,625 shares of the company’s stock valued at $6,320,000 after purchasing an additional 89,896 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.